A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

NCT ID: NCT04991831

Last Updated: 2025-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-28

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this study are to collect the long-term safety and effectiveness data of performing thalamotomy for tremor dominant Parkinson's Disease (TDPD) using the Exablate Neuro system.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a post-approval registry which is required by of the approval under PMA P150038/S006 for the Exablate® Model 4000 (Exablate Neuro) Type 1.0 and Type 1.1 for unilateral thalamotomy in the treatment of medication refractory Tremor Dominant Parkinson's Disease (TDPD). Subjects participating in this registry will have received a unilateral thalamotomy (ventralis medius) prior to enrollment using the commercially available Exablate Neuro for the treatment of Essential tremor and TDPD.

The following assessments will be collected at Baseline,1, 3, 6, and 12 months post Exablate procedure and annually thereafter for 5 years:

* Adverse Events (AEs) (does not apply to Baseline Visit)
* Medication usage
* Clinical Rating Scale for Tremor (CRST) ON medication
* Unified Parkinson's Disease Rating Scale Part III ON medication
* EQ-5D-5L
* WPAI-GH

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tremor Associated With Tremor Dominant Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Post Exablate Neuro Thalamotomy for Tremor Associated with Tremor Dominant Parkinson's Disease

This is a post Exablate Neuro Thalamotomy registry. No intervention is performed under this registry protocol.

Unilateral thalamotomy

Intervention Type DEVICE

Unilateral thalamotomy using focused ultrasound for the treatment of medication-refractory tremor dominant idiopathic Parkinson's Disease.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Unilateral thalamotomy

Unilateral thalamotomy using focused ultrasound for the treatment of medication-refractory tremor dominant idiopathic Parkinson's Disease.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women, age 30 years and older
2. Subject undergoing an Exablate procedure for their planned TDPD treatment; per local institution standard of care.
3. Subject is willing to cooperate with the Registry requirements including compliance with the regimen and completion of all study visits
4. Subject has signed and received a copy of the approved informed consent form

Exclusion Criteria

Subject does not agree to participate or is unlikely to participate for the entirety of the study.
Minimum Eligible Age

30 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

InSightec

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Miami Neuroscience Institute Baptist Health

Miami, Florida, United States

Site Status RECRUITING

Rush University

Chicago, Illinois, United States

Site Status RECRUITING

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status RECRUITING

Weill Cornell Medicine

New York, New York, United States

Site Status RECRUITING

Novant Health Brain & Spine Surgery

Huntsville, North Carolina, United States

Site Status RECRUITING

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status RECRUITING

Miami Valley Hospital

Fairborn, Ohio, United States

Site Status RECRUITING

University of Dundee

Dundee, Scotland, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mark Grassman, Ph.D.

Role: CONTACT

214-630-2000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Justin Sporrer, MD

Role: primary

786-596-2226

Josette Elysée

Role: backup

786-596-1826

Edgar Y Perez

Role: primary

312-942-7391

John Rolston, MD, PhD

Role: primary

Anna Ball

Role: backup

Michael Kaplitt, MD, PhD

Role: primary

Isabella Cipollone

Role: backup

203-917-9918

Charles Munyon, MD

Role: primary

Darren Crawford

Role: backup

Courtney Cannon

Role: primary

216-444-1057

Daniel Gaudin, MD

Role: primary

419-481-6220

Heather Bell

Role: backup

937-208-6013

Tom Gilbertson, PhD MBBS

Role: primary

Kayleigh Anderson

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PD012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.